We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific Inc.'s (TMO - Free Report) second-quarter 2024 adjusted earnings per share (EPS) of $5.37 topped the Zacks Consensus Estimate by 4.9%. The figure also rose 4.3% year over year.
The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.
GAAP EPS was $4.04, up 15.1% on a year-over-year basis.
Revenues in Detail
Revenues in the quarter totaled $10.54 billion, down 1.4% year over year. The top line, however, beat the Zacks Consensus Estimate by 0.3%.
Segment Details
Organic revenues in the reported quarter were 1% lower, while core organic revenues were flat year over year.
Thermo Fisher operates under four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Revenues in the Life Sciences Solutions segment (22.3% of total revenues) declined 4.4% year over year to $2.36 billion, while Analytical Instruments Segment sales (16.9%) rose 1.9% to $1.78 billion. Our model projected revenues of $2.26 billion for the Life Sciences Solutions segment and $1.80 billion for the Analytical Instruments Segment.
Revenues in the Laboratory Products and Biopharma Services segment (54.6%) fell 1.3% to $5.76 billion. Our model projected revenues of $5.83 billion for the segment. The Specialty Diagnostics segment (10.6%) registered 0.7% year-over-year growth in revenues to $1.12 billion. This figure compares with our model’s projection of $1.06 billion for the second quarter.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Gross margin of 42.1% in the second quarter expanded 124 basis points (bps) year over year.
In the quarter, selling, general and administrative expenses rose 0.8% to $1.69 billion. Research and development expenses declined 1.7% to $339 million.
The adjusted operating margin in the quarter was 22.9%, reflecting an improvement of 90 bps.
Financial Position
The company ended second-quarter 2024 with cash and cash equivalents and short-term investments of $8.82 billion compared with $7.25 billion at the end of first-quarter 2024.
Cumulative net cash from operating activities at the end of the second quarter was $3.21 billion compared with $2.27 billion a year ago.
The company raised its adjusted EPS guidance to a new range of $21.29 to $22.07 from its previous guidance of $21.14 to $22.02.
The company now expects 2024 revenues to be in the range of $42.4-$43.3 billion (tapered from the previous guided range of $42.3-$43.3 billion). The Zacks Consensus Estimate for 2024 revenues is pegged at $42.9 billion.
Our Take
Thermo Fisher exited the second quarter of 2024 with better-than-expected results. During the quarter, the company advanced its proven growth strategy by launching a range of high-impact, innovative new products. The newly-introduced analytical instruments products include the Thermo Scientific Stellar mass spectrometer and three new built-for-purpose editions of the Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer tailored to MultiOmics, Structural Biology and BioPharma applications. The company is upbeat about the newly completed acquisition of Olink, a provider of differentiated next-generation proteomic solutions.
Margin expansion was an added upside. The company’s raised 2024 EPS outlook looks encouraging.
On the flip side, the company reported a decline in both reported and organic revenues in the second quarter. The year-over-year decline in Life Science Solutions and Laboratory Products and Biopharma Services revenues was also disappointing.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Globus Medical has an estimated earnings growth rate of 21.6% for 2024 compared with the industry’s 11.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average being 10.8%.
Insulet has an estimated long-term earnings growth rate of 17.9% compared with the industry’s 14.7%. PODD surpassed earnings estimates in each of the trailing four quarters, the average being 83%.
Haemonetics has an estimated fiscal 2025 earnings growth rate of 15.4% compared with the industry’s 12.5%. HAE surpassed earnings estimates in each of the trailing four quarters, the average being 13.2%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
Thermo Fisher Scientific Inc.'s (TMO - Free Report) second-quarter 2024 adjusted earnings per share (EPS) of $5.37 topped the Zacks Consensus Estimate by 4.9%. The figure also rose 4.3% year over year.
The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.
GAAP EPS was $4.04, up 15.1% on a year-over-year basis.
Revenues in Detail
Revenues in the quarter totaled $10.54 billion, down 1.4% year over year. The top line, however, beat the Zacks Consensus Estimate by 0.3%.
Segment Details
Organic revenues in the reported quarter were 1% lower, while core organic revenues were flat year over year.
Thermo Fisher operates under four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Revenues in the Life Sciences Solutions segment (22.3% of total revenues) declined 4.4% year over year to $2.36 billion, while Analytical Instruments Segment sales (16.9%) rose 1.9% to $1.78 billion. Our model projected revenues of $2.26 billion for the Life Sciences Solutions segment and $1.80 billion for the Analytical Instruments Segment.
Revenues in the Laboratory Products and Biopharma Services segment (54.6%) fell 1.3% to $5.76 billion. Our model projected revenues of $5.83 billion for the segment. The Specialty Diagnostics segment (10.6%) registered 0.7% year-over-year growth in revenues to $1.12 billion. This figure compares with our model’s projection of $1.06 billion for the second quarter.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote
Margin Analysis
Gross margin of 42.1% in the second quarter expanded 124 basis points (bps) year over year.
In the quarter, selling, general and administrative expenses rose 0.8% to $1.69 billion. Research and development expenses declined 1.7% to $339 million.
The adjusted operating margin in the quarter was 22.9%, reflecting an improvement of 90 bps.
Financial Position
The company ended second-quarter 2024 with cash and cash equivalents and short-term investments of $8.82 billion compared with $7.25 billion at the end of first-quarter 2024.
Cumulative net cash from operating activities at the end of the second quarter was $3.21 billion compared with $2.27 billion a year ago.
Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth being 16.39%.
Guidance
Thermo Fisher updated its 2024 guidance.
The company raised its adjusted EPS guidance to a new range of $21.29 to $22.07 from its previous guidance of $21.14 to $22.02.
The company now expects 2024 revenues to be in the range of $42.4-$43.3 billion (tapered from the previous guided range of $42.3-$43.3 billion). The Zacks Consensus Estimate for 2024 revenues is pegged at $42.9 billion.
Our Take
Thermo Fisher exited the second quarter of 2024 with better-than-expected results. During the quarter, the company advanced its proven growth strategy by launching a range of high-impact, innovative new products. The newly-introduced analytical instruments products include the Thermo Scientific Stellar mass spectrometer and three new built-for-purpose editions of the Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer tailored to MultiOmics, Structural Biology and BioPharma applications. The company is upbeat about the newly completed acquisition of Olink, a provider of differentiated next-generation proteomic solutions.
Margin expansion was an added upside. The company’s raised 2024 EPS outlook looks encouraging.
On the flip side, the company reported a decline in both reported and organic revenues in the second quarter. The year-over-year decline in Life Science Solutions and Laboratory Products and Biopharma Services revenues was also disappointing.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Insulet (PODD - Free Report) and Haemonetics (HAE - Free Report) . While Globus Medical and Insulet sport a Zacks Rank #1 (Strong Buy) each, Haemonetics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical has an estimated earnings growth rate of 21.6% for 2024 compared with the industry’s 11.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average being 10.8%.
Insulet has an estimated long-term earnings growth rate of 17.9% compared with the industry’s 14.7%. PODD surpassed earnings estimates in each of the trailing four quarters, the average being 83%.
Haemonetics has an estimated fiscal 2025 earnings growth rate of 15.4% compared with the industry’s 12.5%. HAE surpassed earnings estimates in each of the trailing four quarters, the average being 13.2%.